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Background: Cabozantinib, an orally bioavailable inhibitor of tyrosine kinases including MET, AXL, and VEGF receptors, was
assessed in patients with hepatocellular carcinoma (HCC) as part of a phase 2 randomized discontinuation trial with nine tumor-
type cohorts.
Patients and methods: Eligible patients had Child-Pugh A liver function and1 prior systemic anticancer regimen, com-
pleted4 weeks before study entry. The cabozantinib starting dose was 100mg daily. After an initial 12-week cabozantinib
treatment period, patients with stable disease (SD) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 were
randomized to cabozantinib or placebo. The primary endpoint of the lead-in stage was objective response rate (ORR) at week
12, and the primary endpoint of the randomized stage was progression-free survival (PFS).
Results: Among the 41 HCC patients enrolled, the week 12 ORR was 5%, with 2 patients achieving a confirmed partial response
(PR). The week 12 disease control rate (PR or SD) was 66% (Asian subgroup: 73%). Of patients with1 post-baseline scan, 78%
had tumor regression, with no apparent relationship to prior sorafenib therapy. Alpha-fetoprotein (AFP) response (>50% reduc-
tion from baseline) occurred in 9 of the 26 (35%) patients with elevated baseline AFP and1 post-baseline measurement.
Twenty-two patients with SD at week 12 were randomized. Median PFS after randomization was 2.5 months with cabozantinib
and 1.4 months with placebo, although this difference was not statistically significant. Median PFS and overall survival from Day
1 in all patients were 5.2 and 11.5 months, respectively. The most common grade 3/4 adverse events, regardless of attribution,
were diarrhea (20%), hand-foot syndrome (15%), and thrombocytopenia (15%). Dose reductions were utilized in 59% of patients.
Conclusions: Cabozantinib has clinical activity in HCC patients, including objective tumor responses, disease stabilization, and
reductions in AFP. Adverse events were managed with dose reductions.
Trial registration number: NCT00940225.
Key words: hepatocellular carcinoma, cabozantinib, vascular endothelial growth factor receptor, progression-free survival,
overall survival, tumor response
Introduction
The receptor tyrosine kinase MET and its ligand, hepatocyte
growth factor, play important roles in diverse aspects of tumor
pathobiology, including tumor growth, survival, neoangiogene-
sis, invasion, and dissemination [1]. MET pathway activation
and dysregulation have been implicated in multiple cancers,
including hepatocellular carcinoma (HCC) [1, 2], and may play
VC The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use,
distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Annals of Oncology 28: 528–534, 2017
doi:10.1093/annonc/mdw651
Published online 28 February 2017
a role in resistance to antiangiogenic therapy [3–6]. Similarly,
increased expression of the receptor tyrosine kinase AXL has
also been reported in HCC and may promote invasive behavior
[7]. In other settings AXL signaling has been linked to resistance
to VEGF receptor (VEGFR) inhibitors [6]. VEGFRs and their
ligands are central mediators of tumor neoangiogenesis and
lymphangiogenesis [8]. High VEGF levels in both tissue and
serum predict poor disease-free and overall survival (OS) in
HCC [9].
Currently, the only approved systemic therapy for HCC is sora-
fenib, an inhibitor of VEGFRs, RAF, and other protein kinases,
which provides a modest survival benefit for patients with unre-
sectable disease [10]. Other molecularly targeted agents including
several antiangiogenics have failed to prolong survival in phase 3
trials as either first-line therapy compared with sorafenib (suniti-
nib, brivanib, linifanib, erlotinib plus sorafenib) or second-line
therapy following failure of sorafenib (brivanib, everolimus,
ramucirumab) [11]. Agents currently in phase 3 trials include
lenvatinib and nivolumab as first-line treatments and tivantinib
and regorafenib as second-line treatments [12, 13]. Recently,
regorafenib has shown a survival benefit compared with placebo
in this setting with median OS of 10.6 vs 7.8 months [12]. In a
phase 1/2 trial, the immune checkpoint inhibitor nivolumab
demonstrated a 67% disease control rate including two complete
responses (5%) and 6 month overall survival rate of 72% [13].
Cabozantinib (XL184), an orally bioavailable tyrosine kinase
inhibitor (TKI), targets multiple receptor tyrosine kinases,
including VEGFRs, MET, AXL, RET, KIT, and FLT3. In xenograft
models, cabozantinib treatment suppressed MET and VEGFR2
signaling, rapidly induced apoptosis of endothelial and tumor
cells, and resulted in tumor regression [14]. In addition, cabozan-
tinib treatment suppressed HCC tumor growth and metastasis in
a mouse xenograft model [15], and prolonged survival in a MET-
driven transgenic mouse model of HCC (D. Yang, J.M. Bishop,
personal communication, August 2010).
In a phase 1 trial, cabozantinib treatment resulted in tumor re-
gression in multiple cancer types [16]. In phase 3 trials cabozanti-
nib significantly improved PFS and objective response rate
(ORR) compared with placebo in patients with progressive meta-
static medullary thyroid cancer and significantly improved PFS,
ORR, and OS compared with everolimus in patients with
advanced renal cell carcinoma (RCC) previously treated with a
VEGFR TKI [17, 18].
Based on cabozantinib’s broad clinical activity in multiple
tumor types seen in an earlier phase 1 study [16], a phase 2
randomized discontinuation trial (RDT) was conducted in nine
tumor types, including HCC (NCT00940225) [19]. This report
describes results from the HCC cohort of the phase 2 RDT.
Patients and methods
Patients
Eligible patients had HCC diagnosed by core biopsy or appropriate imaging
technique [computed tomography (CT) or magnetic resonance imaging
(MRI)], measurable disease by Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.0 with protocol-defined modifications [20], and, unless
newly diagnosed and never treated, evidence of progressive disease (PD) by
CT, MRI, or bone scan at screening. Additional inclusion/exclusion criteria
have been previously described (see supplementary Patients and Methods,
available at Annals of Oncology online) [21].
Study design
All patients received cabozantinib at a starting dose of 100 mg daily during a
12-week lead-in phase. At week 12, patients with SD were randomized to
cabozantinib or placebo, patients with a PR could continue open-label cabo-
zantinib treatment, and patients with PD at or before week 12 discontinued
treatment. See supplementary Figure S1, available at Annals of Oncology online
for additional study design details.
The primary endpoint of the lead-in phase was ORR at week 12, and the
primary endpoint of the randomized phase was PFS. Secondary endpoints
included safety, tolerability, and PFS and OS of the entire cabozantinib-
treated population. An additional exploratory endpoint was assessment of
changes in serum alpha-fetoprotein (AFP).
Study assessments
Efficacy assessments included radiographic soft-tissue imaging with CT and/
or MRI of the chest/abdomen with investigator-assessed response using
RECIST 1.0. Other clinical assessments included medical and cancer history,
physical examination, vital signs, body weight, electrocardiography, Eastern
Cooperative Oncology Group (ECOG) performance status, safety laboratory
values (serum chemistry, hematology, coagulation, and urinalysis), concomi-
tant medications, adverse events (AEs), and information on subsequent anti-
cancer treatment. Pre-dose pharmacokinetic (PK) blood samples were
collected at baseline and after 6 and 12 weeks for determining plasma cabozan-
tinib concentrations, with additional week 2 and 4 assessments in some
patients.
Study oversight
A study oversight committee monitored efficacy during lead-in, and an inde-
pendent data monitoring committee reviewed safety during the blinded
randomized stage. The study oversight committee was empowered to suspend
randomization by cohort based on data review.
Statistical considerations
Statistical considerations for this RDT have been previously described
(see supplementary Patients and Methods, available at Annals of Oncology on-
line) [21].
Results
Patient characteristics and disposition
The RDT enrolled 526 patients across nine tumor-type cohorts.
Results from 41 patients with HCC enrolled from the United
States, Belgium, and Taiwan are presented. Median follow-up was
19.4 months. Baseline demographic and clinical characteristics are
summarized in Table 1. Thirty-two patients had1 line of prior
systemic anticancer therapy; of these, 24 had prior TKIs (including
sorafenib in 22 patients). Among the 41 patients enrolled to receive
open-label cabozantinib during the 12-week lead-in, 12 discontin-
ued study treatment before week 12, seven continued open-label
cabozantinib after week 12, and 22 were randomized to receive
cabozantinib (n¼ 10) or placebo (n¼ 12). See supplementary
Figure S2, available at Annals of Oncology online for additional de-
tails of patient disposition. The data cutoff date for the results pre-
sented in this publication was December 16, 2011.
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While the goal of the study was to randomize approximately 70
patients per cohort (see supplementary Patients and Methods,
available at Annals of Oncology online), randomization was halted
early for all cohorts due to the high rates of tumor regression and
the observation of symptomatic progression in individual patients
randomized to placebo in several of the disease cohorts [20].
Tumor response
The primary endpoint for the open-label lead-in phase was ORR
per RECIST 1.0 at week 12. Among 41 enrolled patients, two had
a confirmed partial response (PR) at week 12, resulting in an
ORR of 5%. Thirty-one patients had SD as a best response at week
6 and/or week 12 (SD), and three had PD (Table 2). Additionally,
one patient randomized to placebo at week 12 had a PR at week
18. The disease control rate (DCR: PR or SD) at week 12 was 66%
overall (Table 2) and 73% (11 of 15) in Asian patients. Thirty-six
assessable patients had1 post-baseline assessment during the
initial 12 weeks of therapy, and 28 (78%) of these patients had1
scan demonstrating a reduction of measurable disease (Figure
1A). Nine of the 26 (35%) patients with1 post-baseline meas-
urement had AFP responses (defined as>50% reduction from
baseline in patients with AFP>20 ng/ml at baseline; Figure 1B).
Progression-free and overall survival
Among the patients who had SD at week 12 (n¼ 22), 12 patients
were randomized to placebo and 10 to cabozantinib. No significant
difference in PFS was observed between the two groups. Median PFS
from time of randomization was 2.5 months [95% confidence inter-
val (CI), 1.3–6.8 months] for cabozantinib patients and 1.4 months
(95% CI, 1.3–4.2 months) for placebo (data not shown).
For the analysis of overall PFS from the first dose of cabozanti-
nib, the piecewise estimation method described by Ratain et al.
[22] was used (see supplementary Patients and Methods, avail-
able at Annals of Oncology online). Median overall PFS for all 41
treated patients from the start of the study was 5.2 months (data
not shown). Median overall PFS for sorafenib-pretreated
(n¼ 22) versus sorafenib-naive (n¼ 19) patients was 5.5 versus
4.2 months, respectively (Figure 2A), and 4.2 versus 5.5 months
for Asian (n¼ 15) versus non-Asian (n¼ 26) patients, respect-
ively (data not shown). Median OS for all 41 treated patients was
11.5 months (95% CI, 7.3–15.6 months; Figure 2B).
Safety
Table 3 summarizes AEs reported during lead-in regardless of at-
tribution. All patients had1 AE; most experienced>1 event.
Table 1. Baseline demographic and clinical characteristics of HCC patients
Entire treated population
(n 5 41)
Characteristic Patients, n (%)
Age (years)
Median (range) 60 (32–82)
Sex
Male 31 (76)
Female 10 (24)
Race
Asian 15 (37)
Non-Asian 26 (63)
ECOG performance status
0 18 (44)
1 23 (56)
Etiology of disease
Hepatitis B 10 (24)
Hepatitis Ca 10 (24)
Alcohol-related 6 (15)
Other/unknown 15 (37)
Measurable disease 41 (100)
Extrahepatic spread 30 (73)
Hypersplenic/cytopenic
Hemoglobin <11 g/dL 16 (39)
Thrombocytopenia 16 (39)
AFP (ng/ml)
Median (range) 368 (3–259, 298)
Prior lines of systemic therapy
0 9 (22)
1 30 (73)
2 2 (5)
Prior anticancer therapy
Tyrosine kinase inhibitor 24 (59)
Sorafenib 22 (54)
Surgical resection 17 (42)
Locoregional therapyb 21 (51)
AFP, alpha-fetoprotein; ECOG, Eastern Cooperative Oncology Group.
aTwo hepatitis C patients also had alcohol-related etiology.
bLocoregional therapy includes transarterial embolization, percutan-
eous ethanol injection radiofrequency ablation, and radiotherapy
applied to extrahepatic metastatic lesions.
Table 2. Summary of week 12 response in HCC patients by RECIST 1.0
(n5 41)
Parameter Patients, n (%)
RECIST response
Confirmed partial response 2a (5)
Stable diseaseb 31 (76)
Progressive disease 3 (7)
Missing data 4 (10)
Unable to evaluate 1 (2)
Week 12 disease controlc 27 (66)
AFP response evaluabled 26
>50% Decrease from baseline 9 (35)
AFP, alpha-fetoprotein; RECIST, Response Evaluation Criteria in Solid
Tumors.
aIn addition, one patient assessed with stable disease at week 12 and
randomized to placebo had a confirmed partial response at week 18.
bStable disease at week 6 and/or week 12.
cDisease control defined as confirmed partial responseþ stable disease
at week 12.
dBaseline AFP20 ng/ml.
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Figure 1. (A) Best change from baseline in investigator-assessed measurements of soft-tissue lesions using Response Evaluation Criteria in Solid
Tumors (version 1.0) was determined for hepatocellular carcinoma (HCC) patients who had baseline and at least one post-baseline radiographic
scan in the first 12 weeks (n¼ 36). A reduction in the sum of measurable lesions was reported for 78% of assessable patients. Change in measur-
able disease was independent of prior treatment with sorafenib. (B) Best change from baseline in alpha-fetoprotein (AFP) measurements was
determined for HCC patients who had baseline AFP20 ng/ml (n¼ 26). aConfirmed partial response. bIncrease>100% from baseline.
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Figure 2. Kaplan–Meier estimates of (A) progression-free survival (PFS) in all patients with HCC by sorafenib pretreatment status. (B) Overall
survival (OS) for all patients with HCC.
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The most common grade3 AEs were diarrhea (20%), hand-
foot syndrome (15%), thrombocytopenia (15%), hypertension
(10%), and transaminase elevation (10%). There were no grade 5
AEs considered related to study treatment, and no clinically sig-
nificant bleeding events were reported during the lead-in period.
No patient discontinued study treatment due to an AE during the
12-week lead-in. Dose reductions were employed in 59% of pa-
tients. The median average daily dose was 66 mg/day, and the
median time to first dose reduction was 39.5 days.
Pharmacokinetics
The pre-dose mean plasma concentration (6 standard deviation)
of cabozantinib was 861 (6375) ng/ml with a corresponding per-
centage coefficient of variation of 43.6% in patients (n¼ 14) who
received at least 13 of 15 uninterrupted 100-mg/day cabozantinib
doses over the 2 weeks before the PK sampling visit on week 6.
Cabozantinib exposure in the HCC cohort of the RDT was similar
to the other disease-specific cohorts in the study.
Discussion
Cabozantinib inhibits targets considered important for HCC
progression and resistance to first-line sorafenib therapy includ-
ing VEGFRs, MET, and AXL. In this RDT, cabozantinib showed
preliminary signs of clinical activity in both sorafenib-pretreated
and sorafenib-naive patients with advanced HCC.
In HCC patients, cabozantinib demonstrated a week 12 ORR
of 5% by RECIST 1.0 and a week 12 DCR of 66%. During the
lead-in phase, cabozantinib treatment resulted in a reduction in
target lesions from baseline in 78% of assessable HCC patients.
Cabozantinib activity in advanced HCC is further supported by
the 35% of patients achieving>50% AFP reduction, as AFP re-
sponse is associated with tumor response and survival across
stages and treatment modalities in HCC [23–25].
In the randomized population, there was no significant difference
in median PFS between the cabozantinib and placebo arms, al-
though the trend favored PFS improvement in the cabozantinib
arm. In the entire cabozantinib-treated population, median PFS
was 5.2 months with similar results across multiple subsets including
Asian versus non-Asian and sorafenib-pretreated versus sorafenib-
naive populations. Median OS for all cabozantinib-treated patients
was 11.5 months (95% CI, 7.3–15.6 months).
The most frequent AEs in this cohort (e.g. diarrhea, weight
loss, hand-foot syndrome) were mainly mild to moderate in se-
verity and consistent with those observed in other cohorts and
with sorafenib in HCC patients.
Mean steady-state pre-dose plasma cabozantinib concentra-
tion and variability were consistent with other cohorts and other
cabozantinib studies, suggesting that cabozantinib plasma PK
was not markedly altered in HCC patients. In a separate study of
subjects with hepatic impairment, geometric least squared mean
ratios for plasma cabozantinib AUC0-inf for impaired to normal
organ function cohorts were 81% and 63% higher in subjects
with mild and moderate hepatic impairment, respectively [26].
The RDT design allows assessment of clinical activity while
minimizing exposure to placebo, creates a controlled trial with-
out upfront randomization, and decreases the heterogeneity of
the randomized population, thus increasing statistical power
with fewer patients [22]. The goal of this study was to identify in-
dications where cabozantinib exhibits disease stabilizing activity,
however, the high rate of tumor regression found for several
tumor types led to an early halt of the randomized phase of the
study. Therefore, the targeted patient accrual was not met, and
the full utility of the RDT trial design was not realized.
Based on these preliminary signs of clinical activity, a phase 3,
randomized, double-blind, controlled trial has been initiated com-
paring cabozantinib to placebo in patients with HCC who have
received prior sorafenib therapy (CELESTIAL; NCT01908426).
Clinical development of cabozantinib for this patient population is
also supported by preclinical studies in HCC models that demon-
strate the importance of VEGFRs, MET, and AXL in tumor pro-
gression [2, 15] and MET in acquired resistance to anti-angiogenic
therapy including sorafenib [3]. Furthermore, in patients with
advanced RCC, cabozantinib was effective following treatment
with VEGFR inhibitors, significantly improving PFS, ORR, and
OS vs everolimus [17].
In the RDT study patients received a cabozantinib starting dose
of 100 mg daily, and dose reductions were used to manage adverse
events in 59% of patients in the HCC cohort. The median average
daily dose for patients in the HCC cohort was 66 mg/day with a
median time to first dose reduction of 39.5 days. Even with dose re-
ductions, patients maintained disease control as shown by the high
DCR at week 12. These data supported the choice of 60 mg daily as
the starting dose for the ongoing phase 3 trial CELESTIAL.
Table 3. Most frequently reported adverse events in HCC patients during
lead-in stage regardless of causality
All grades Grade 3
(n5 41) (n5 41)
Adverse eventa Patients, n (%)
Any adverse event 41 (100) 35 (85)
Diarrhea 26 (63) 8 (20)
Hand-foot syndrome 23 (56) 6 (15)
Fatigue 23 (56) 1 (2)
Thrombocytopenia 15 (37) 6 (15)
Nausea 15 (37) 1 (2)
Vomiting 15 (37) 1 (2)
Decreased appetite 12 (29) 0 (0)
Aspartate aminotransferase increased 11 (27) 4 (10)
Hypertension 10 (24) 4 (10)
Rash 10 (24) 0 (0)
Asthenia 9 (22) 3 (7)
Weight decreased 9 (22) 1 (2)
Constipation 9 (22) 0 (0)
Hair color changes 9 (22) 0 (0)
CTCAE, Common Terminology Criteria for Adverse Events; HCC, hepa-
tocellular carcinoma; MedDRA, Medical Dictionary for Regulatory
Activities.
aMedDRA v. 14.1 Preferred Terms (converted to US spelling), CTCAE v.
3.0 grading.
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In conclusion, cabozantinib showed preliminary signs of activity
in patients with sorafenib-pretreated or sorafenib-naive HCC. These
results include observation of objective responses, a high disease
control rate, and AFP responses that were independent of prior anti-
VEGFR targeted therapy or ethnicity. Although the small sample
size of the HCC cohort in this RDT limits interpretation of the cur-
rent findings, further studies are warranted to confirm these results
and further evaluate cabozantinib in HCC patients.
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